Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
A phase 1/2 trial of Venetoclax and Azacitidine in advanced solid tumours, run by Sellas Life Sciences Group, now recruiting.
Overview
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML is a phase 1/2 interventional study registered as NCT04588922 by Sellas Life Sciences Group, with 160 participants planned, started 2021-05-10 and due to reach its primary completion in 2026-12-30. Interventions recorded: SLS009, venetoclax and azacitidine.
Similar pages
not linked directly; found by shared links- TrialGalinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Shares Galena Biopharma, Azacitidine, Venetoclax and the tag pipeline.
- TrialA Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax and the tag pipeline.
- TrialFCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms
Shares Azacitidine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax and the tag pipeline.
- TrialIMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax and the tag pipeline.
- TrialA Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Shares Azacitidine, Venetoclax and the tag pipeline.
- TrialStudy of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
Shares Azacitidine, Venetoclax and the tag pipeline.
- TrialA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Shares Azacitidine, Venetoclax and the tag pipeline.